PONCIRUS-PHARMA®
Frost-hardy Poncirus trifoliata.
Five pharmaceutical research directions across flavonoids (poncirin, naringin), limonoids (limonin, auraptene), and coumarins (imperatorin, phellopterin). Moldovan winter stress yields enriched defensive-metabolite concentrations distinct from tropically-cultivated equivalents.
Poncirus trifoliata — trifoliate orange, sometimes called hardy citrus — carries a distinct phytochemical profile rarely found in commercial citrus crops. PONCIRUS-PHARMA® is the TEHNOFARM® programme cultivating a Moldovan-adapted frost-hardy line whose specific stress profile yields enriched concentrations of defensive metabolites compared with tropically-cultivated equivalents.
Active compounds
Across leaf, young shoot, bark, and fruit fractions, Poncirus trifoliata contains:
| Class | Compounds |
|---|---|
| Flavonoids | Poncirin (signature compound), naringin, hesperidin, neohesperidin |
| Limonoids and terpenoids | Limonin, nomilin, auraptene |
| Coumarins | Imperatorin, phellopterin |
| Pectins | Pharmaceutical-grade pectin fractions |
| Essential oils | Leaf and peel fractions |
Pharmaceutical research directions
The programme operates across five research directions, each tracking distinct pharmacological literature:
1. Anti-inflammatory and immunomodulatory applications
Chronic inflammatory states, hepatic and gastrointestinal research frameworks.
2. Oncology R&D
Pre-clinical research interest in flavonoid and limonoid apoptotic and antimutagenic activity. Research stage only; no clinical claims.
3. Antimicrobial and antiviral
Phyto-pharmaceutical and natural antiseptic applications.
4. Antioxidant fraction
Nutraceutical and anti-ageing research, cell-membrane protective applications.
5. Gastrointestinal motility
Poncirus trifoliata has documented traditional pharmacopoeia presence in Chinese (Zhi Shi), Korean (Kijitsu), and Japanese herbal medicine for gastric motility and atonic conditions.
Why frost-hardy cultivation
Plants cultivated under genuine winter conditions accumulate higher concentrations of defensive metabolites. The result is a richer flavonoid profile and a potentially higher pharmaceutical-grade fraction yield than tropically-cultivated equivalents would produce. The Moldovan climate produces a stress-validated phytochemical profile that distinguishes the programme commercially.
Status
Field validation complete on the Moldovan frost-hardy cultivar. Cultivation phase entering scale-up. Detailed analytical profiling continues under NORD NUC operational management.
Engagement
Pharmaceutical extractors, nutraceutical buyers, traditional-medicine-aligned research procurement: contact@tehnofarm.md. Subject line: PONCIRUS-PHARMA® inquiry.